← Back to Search

Monoclonal Antibodies

BI 836880 for Age-Related Macular Degeneration

Phase 1 & 2
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new medicine injected into the eye for people with a certain eye condition who haven't responded to other treatments. The goal is to see if it can help control new blood vessel growth and improve vision.

Eligible Conditions
  • Age-Related Macular Degeneration (AMD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: BI 836880Experimental Treatment1 Intervention
Single Rising Dose part followed by a Multiple Rising Dose part
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BI 836880
2016
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,534 Previous Clinical Trials
11,380,098 Total Patients Enrolled

Media Library

BI 836880 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03861234 — Phase 1 & 2
Age-Related Macular Degeneration Research Study Groups: BI 836880
Age-Related Macular Degeneration Clinical Trial 2023: BI 836880 Highlights & Side Effects. Trial Name: NCT03861234 — Phase 1 & 2
BI 836880 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03861234 — Phase 1 & 2
~7 spots leftby Oct 2025